JP6949106B2 - 抗ｖｅｇｆ−ａ抗体ならびにそれらの使用 - Google Patents

抗ｖｅｇｆ−ａ抗体ならびにそれらの使用 Download PDF

Info

Publication number
JP6949106B2
JP6949106B2 JP2019510850A JP2019510850A JP6949106B2 JP 6949106 B2 JP6949106 B2 JP 6949106B2 JP 2019510850 A JP2019510850 A JP 2019510850A JP 2019510850 A JP2019510850 A JP 2019510850A JP 6949106 B2 JP6949106 B2 JP 6949106B2
Authority
JP
Japan
Prior art keywords
antibody
binding
hcdr3
lcdr1
lcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019510850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528074A5 (enExample
JP2019528074A (ja
Inventor
チン レオウ，チン
チン レオウ，チン
ディマシ，ナッザレノ
コフマン，カレン
ツイ，ピン
ガオ，チャンショウ
セペダ，マリオ，エー
ミッテルマン，エイドリアン シュワルツ
ミッテルマン，エイドリアン シュワルツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2019528074A publication Critical patent/JP2019528074A/ja
Publication of JP2019528074A5 publication Critical patent/JP2019528074A5/ja
Priority to JP2021152836A priority Critical patent/JP7277531B2/ja
Application granted granted Critical
Publication of JP6949106B2 publication Critical patent/JP6949106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019510850A 2016-08-23 2017-08-22 抗ｖｅｇｆ−ａ抗体ならびにそれらの使用 Active JP6949106B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021152836A JP7277531B2 (ja) 2016-08-23 2021-09-21 抗ｖｅｇｆ－ａ抗体ならびにそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378391P 2016-08-23 2016-08-23
US62/378,391 2016-08-23
PCT/EP2017/071106 WO2018037001A1 (en) 2016-08-23 2017-08-22 Anti-vegf-a antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021152836A Division JP7277531B2 (ja) 2016-08-23 2021-09-21 抗ｖｅｇｆ－ａ抗体ならびにそれらの使用

Publications (3)

Publication Number Publication Date
JP2019528074A JP2019528074A (ja) 2019-10-10
JP2019528074A5 JP2019528074A5 (enExample) 2020-10-01
JP6949106B2 true JP6949106B2 (ja) 2021-10-13

Family

ID=59677248

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019510850A Active JP6949106B2 (ja) 2016-08-23 2017-08-22 抗ｖｅｇｆ−ａ抗体ならびにそれらの使用
JP2021152836A Active JP7277531B2 (ja) 2016-08-23 2021-09-21 抗ｖｅｇｆ－ａ抗体ならびにそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021152836A Active JP7277531B2 (ja) 2016-08-23 2021-09-21 抗ｖｅｇｆ－ａ抗体ならびにそれらの使用

Country Status (10)

Country Link
US (2) US10919958B2 (enExample)
EP (2) EP3783022A3 (enExample)
JP (2) JP6949106B2 (enExample)
KR (1) KR102538827B1 (enExample)
CN (1) CN109863172B (enExample)
AU (2) AU2017315076B2 (enExample)
CA (1) CA3034576A1 (enExample)
ES (1) ES2836286T3 (enExample)
IL (1) IL264961B2 (enExample)
WO (1) WO2018037001A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7485273B2 (ja) * 2020-06-25 2024-05-16 国立大学法人 鹿児島大学 抗ｖｅｇｆ－ａ抗体による癌に対する治療応答性を予測又は決定するための方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP2338915A3 (en) * 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
ES2236634T3 (es) * 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
US20110076279A1 (en) * 2006-10-20 2011-03-31 Schering Corporation Fully human anti-vegf antibodies and methods of using
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2604280A3 (en) * 2008-03-27 2013-10-16 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN102276722B (zh) * 2011-01-14 2013-05-08 中国科学院北京基因组研究所 新型血管内皮生长因子人源化单克隆抗体
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
ES2749349T3 (es) * 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas

Also Published As

Publication number Publication date
AU2017315076B2 (en) 2020-10-08
EP3504236B1 (en) 2020-09-23
JP2019528074A (ja) 2019-10-10
AU2020289850A1 (en) 2021-01-28
US10919958B2 (en) 2021-02-16
JP7277531B2 (ja) 2023-05-19
AU2020289850B2 (en) 2024-06-06
CN109863172B (zh) 2022-08-26
US11634483B2 (en) 2023-04-25
KR20190040029A (ko) 2019-04-16
AU2017315076A1 (en) 2019-04-04
EP3783022A2 (en) 2021-02-24
IL264961B2 (en) 2025-02-01
JP2022008447A (ja) 2022-01-13
EP3783022A3 (en) 2021-06-30
CN109863172A (zh) 2019-06-07
IL264961A (enExample) 2019-04-30
IL264961B1 (en) 2024-10-01
US20210147531A1 (en) 2021-05-20
CA3034576A1 (en) 2018-03-01
US20190202903A1 (en) 2019-07-04
KR102538827B1 (ko) 2023-05-31
WO2018037001A1 (en) 2018-03-01
ES2836286T3 (es) 2021-06-24
EP3504236A1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
US11566068B2 (en) Nucleic acids encoding bispecific anti-VEGF and anti-ANG2 antibodies and uses thereof
KR20180068952A (ko) 신규한 항-인간 gpvi 항체 및 이의 용도
JP7277531B2 (ja) 抗ｖｅｇｆ－ａ抗体ならびにそれらの使用
HK40047851A (en) Anti-vegf-a antibodies and uses thereof
HK40008333B (en) Anti-vegf-a antibodies and uses thereof
HK40008333A (en) Anti-vegf-a antibodies and uses thereof
HK40010498A (en) Anti-vegf-a antibodies and uses thereof
HK40010498B (en) Anti-vegf-a antibodies and uses thereof
RU2773819C2 (ru) Белок, связанный с гликопротеином человека, композиция, фармацевтическая композиция, вектор экспрессии
HK40008334A (en) Anti-vegf-a and anti-ang2 antibodies and uses thereof
HK40008334B (zh) 抗vegf-a和抗ang2抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210824

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210921

R150 Certificate of patent or registration of utility model

Ref document number: 6949106

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250